Salwa Alhammadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Salwa Alhammadi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Aliya Szpindel
McGill University
1 shared publication - Colin Chalk
McGill University
1 shared publication - Leonardo Furtado Freitas
Division of Clinical Neuroradiology, Department of Radiology, Florida International University Herbert Wertheim College of Medicine, Miami, USA
1 shared publication - Márcio Luís Duarte
Diagnósticos da América S. A., São Paulo (SP), Brazil.
1 shared publication - Tianyu Zhang
Beth Israel Deaconess Medical Center Boston Massachusetts USA
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by Universidad Nacional de Córdoba in Revista de la Facultad de Ciencias Médicas de Córdoba
- Vol. 83 (2) , e48628
A double threat
A 73-year-old immunocompromised woman with a history of heart transplant presented with cognitive decline and left-sided neurological deficits. Imaging revealed atypical brain lesions. Initial biopsy was inconclusive. Despite extensive infectious workup, diagnosis remained unclear until a second brain biopsy confirmed central nervous system toxoplasmosis and cytomegalovirus (CMV) encephalitis. Treatment with antiparasitic and antiviral agents was initiated, but the patient’s condition deteriorated, leading to palliative care. This case highlights diagnostic challenges in immunocompromised patients, the importance of considering atypical presentations of CNS infections, and the potential necessity of repeat biopsies when initial evaluations are non-diagnostic.
- 26 June 2026
- Published by Universidad Nacional de Córdoba in Revista de la Facultad de Ciencias Médicas de Córdoba
- Vol. 83 (2) , e48628
Open AccessA double threat
A 73-year-old immunocompromised woman with a history of heart transplant presented with cognitive decline and left-sided neurological deficits. Imaging revealed atypical brain lesions. Initial biopsy was inconclusive. Despite extensive infectious workup, diagnosis remained unclear until a second brain biopsy confirmed central nervous system toxoplasmosis and cytomegalovirus (CMV) encephalitis. Treatment with antiparasitic and antiviral agents was initiated, but the patient’s condition deteriorated, leading to palliative care. This case highlights diagnostic challenges in immunocompromised patients, the importance of considering atypical presentations of CNS infections, and the potential necessity of repeat biopsies when initial evaluations are non-diagnostic.
- Open Access
- 7 January 2026
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1-5
Preoperative Management of Patients With Myasthenia Gravis: A Review of the Evidence
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by fatigable weakness and increased perioperative vulnerability. Postoperative myasthenic crisis, defined as respiratory failure requiring prolonged ventilation or re-intubation, remains a feared complication after surgical procedures such as thymectomy. The efficacy of preoperative interventions such as intravenous immunoglobulin (IVIg) and plasmapheresis remains uncertain. This review examines the evidence supporting risk stratification tools and immunomodulatory strategies to prevent postoperative myasthenic crisis. A comprehensive literature review was conducted focusing on studies evaluating the incidence, risk factors and preventive strategies for postoperative myasthenic crisis in MG patients. Particular emphasis was placed on clinical predictive models and randomized trials assessing preoperative IVIg and plasmapheresis. Recent data suggest the incidence of postoperative myasthenic crisis has declined to below 10%, largely due to advances in surgical technique and perioperative care. Established risk factors include bulbar involvement, reduced pulmonary function and prior crises. Risk prediction models such as the Leuzzi and Kanai scores offer clinically useful stratification. While older retrospective studies favored preoperative plasmapheresis, meta-analyses and randomized trials have yielded mixed results. Randomized trials of IVIg have shown no significant benefit in well-controlled patients, and both interventions carry notable risks and costs. Current evidence does not support the routine use of IVIg or plasmapheresis prior to surgery in all MG patients. A targeted, risk-based approach guided by validated predictive models is recommended to minimize unnecessary interventions and health care system costs.
- 7 January 2026
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1-5
Open AccessPreoperative Management of Patients With Myasthenia Gravis: A Review of the Evidence
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by fatigable weakness and increased perioperative vulnerability. Postoperative myasthenic crisis, defined as respiratory failure requiring prolonged ventilation or re-intubation, remains a feared complication after surgical procedures such as thymectomy. The efficacy of preoperative interventions such as intravenous immunoglobulin (IVIg) and plasmapheresis remains uncertain. This review examines the evidence supporting risk stratification tools and immunomodulatory strategies to prevent postoperative myasthenic crisis. A comprehensive literature review was conducted focusing on studies evaluating the incidence, risk factors and preventive strategies for postoperative myasthenic crisis in MG patients. Particular emphasis was placed on clinical predictive models and randomized trials assessing preoperative IVIg and plasmapheresis. Recent data suggest the incidence of postoperative myasthenic crisis has declined to below 10%, largely due to advances in surgical technique and perioperative care. Established risk factors include bulbar involvement, reduced pulmonary function and prior crises. Risk prediction models such as the Leuzzi and Kanai scores offer clinically useful stratification. While older retrospective studies favored preoperative plasmapheresis, meta-analyses and randomized trials have yielded mixed results. Randomized trials of IVIg have shown no significant benefit in well-controlled patients, and both interventions carry notable risks and costs. Current evidence does not support the routine use of IVIg or plasmapheresis prior to surgery in all MG patients. A targeted, risk-based approach guided by validated predictive models is recommended to minimize unnecessary interventions and health care system costs.